Key result
Benzbromarone increased the reactive hyperemia index compared to febuxostat, suggesting greater benefits on endothelial function in patients with hyperuricemia.
Why the study?
Hyperuricemia is associated with vascular endothelial dysfunction, but the effects of urate-lowering medicines on endothelial function have not been fully elucidated.
Does benzbromarone improve endothelial function compared to febuxostat in patients with hyperuricemia?
RCT (n=24)
Open-label
Envelope method
No
Does benzbromarone improve endothelial function compared to febuxostat in patients with hyperuricemia?
Benzbromarone improves endothelial function and increases adiponectin levels more than febuxostat in patients with hyperuricemia, suggesting potential cardiovascular benefits beyond urate lowering.
Answers are grounded in this paper and cite their sources.
Benzbromarone may be preferred over febuxostat for endothelial benefits in hyperuricemia; extends RCT evidence on differential vascular effects of urate-lowering agents.
Uric acid is generated with reactive oxygen species via xanthine oxidase (XO), and hyperuricemia, which is identified as the excess of uric acid in the blood, has been associated with vascular endothelial dysfunction. However, the effects of urate-lowering medicines on endothelial function have not been fully elucidated. Thus this study determined and compared the effects of benzbromarone (urate transporter 1 inhibitor) and febuxostat (XO inhibitor) on endothelial function.
No takes yet. Share an insight, caveat, or question.
Nakata et al. (2020) conducted an RCT in Hyperuricemia (n=24). Benzbromarone vs. Febuxostat was evaluated on Change in reactive hyperemia index (RHI) (p=0.026). Benzbromarone increased the reactive hyperemia index compared to febuxostat, suggesting greater benefits on endothelial function in patients with hyperuricemia.
Synapse has enriched 10 related papers. Consider them for comparative context: